Rovalpituzumab tesirine April 13, 2017 Rovalpituzumab tesirine Trade Name Orphan Indication Small cell lung cancer EU Market Approval EU EU Designation Date 2016-05-30 00:00:00 Sponsor AbbVie Ltd
